KD019 and Trastuzumab in Patients With Esophagus, Gastroesophageal Junction and Stomach Cancer
NCT02205463
·
clinicaltrials.gov ↗
PHASE1
Phase
WITHDRAWN
Status
OTHER
Sponsor class
Stopped
IND application withdrawn
Conditions
Esophageal Cancer
Stomach Cancer
Interventions
DRUG:
KD019
Sponsor
NYU Langone Health